Your browser doesn't support javascript.
loading
A Randomized Controlled Trial of OPT-302, a VEGF-C/D Inhibitor for Neovascular Age-Related Macular Degeneration.
Jackson, Timothy L; Slakter, Jason; Buyse, Marc; Wang, Kun; Dugel, Pravin U; Wykoff, Charles C; Boyer, David S; Gerometta, Michael; Baldwin, Megan E; Price, Clare F.
Afiliação
  • Jackson TL; Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom. Electronic address: t.jackson1@nhs.net.
  • Slakter J; The Digital Angiographic Reading Center (DARC), New York, New York.
  • Buyse M; International Drug Development Institute (IDDI), Louvain-la-Neuve, Belgium.
  • Wang K; International Drug Development Institute (IDDI), Louvain-la-Neuve, Belgium.
  • Dugel PU; Retinal Consultants of Arizona, Phoenix, Arizona; University of Southern California, Los Angeles, California.
  • Wykoff CC; Retina Consultants of Texas, Houston, Texas.
  • Boyer DS; Retina-Vitreous Associates Medical Group, Beverly Hills, California.
  • Gerometta M; Opthea Limited, Melbourne, Australia.
  • Baldwin ME; Opthea Limited, Melbourne, Australia.
  • Price CF; Opthea Limited, Melbourne, Australia.
Ophthalmology ; 130(6): 588-597, 2023 06.
Article em En | MEDLINE | ID: mdl-36754174
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Degeneração Macular Exsudativa / Ranibizumab Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Revista: Ophthalmology Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Degeneração Macular Exsudativa / Ranibizumab Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Revista: Ophthalmology Ano de publicação: 2023 Tipo de documento: Article